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Introduction: Smoking cessation promotes health benefits and, despite cigarette smoking be
an important pro inflammatory stimulus, there are few studies concerning the nasal and sys-
temic inflammation; as well as the mucociliary clearance behavior in smokers after short
period of smoking cessation.
Aim: To evaluate the nasal and systemic inflammatory markers and mucociliary clearance
behavior after 30 days of cigarette smoking abstinence.
Methods: Twenty-five smokers were included and divided into two groups: abstinent smokers
(nZ 14) and current smokers (nZ 11). Tumor necrosis factor alpha (TNF-a), interleukin (IL)-6,
IL-8 and IL-10 were measured on nasal lavage and blood serum samples by ELISA at baseline
and after 30 days. The mucociliary clearance, exhaled carbon monoxide (exCO) and carboxy-
hemoglobin (HbCO) were also measured at the same moments.nto de Fisioterapia, Universidade Estadual Paulista, Roberto Simonsen Street, n 305, 19060-900
l. Tel.: þ55 18 32214818; fax: þ55 18 32218212.
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1000 F.M.M. Rodrigues et al.Results: There was a decrease of TNF-a level only in blood serum at 30 days of abstinence
compared to current smokers. The mucociliary clearance improved and there was a reduction
in exCO and HbCO (p < 0.05 for all) after 30 days of smoking cessation.
Conclusion: The short term smoking abstinence decreased systemic inflammation and
improved nasal mucociliary clearance, despite not having changed the nasal inflammation.
ª 2014 Elsevier Ltd. All rights reserved.Introduction
Smoking cessation services are crucial tools in public
health, once tobacco use is the major cause of preventable
morbidity and mortality. It is responsible of nearly 6 million
of deaths and causes hundreds of billions of dollars of
economic damage worldwide each year. Over the course of
the 21st century, the number of deaths can reach a billion,
unless urgent action is taken [1].
There are known substantial benefits of smoking cessa-
tion, such as decreased risk of death, coronary heart dis-
ease and stroke, decreased lung function decline, improved
quality of life, as well as changes in immune response with
increased anti-inflammatory mediators [2e4].
Quitting smoking interrupts the continuous exposure to
several chemicals present in the cigarette smoke that cause
carcinogenic, mutagenic, toxic and irritant effects and a
sustained inflammatory response, which can lead in respi-
ratory epithelium’s damage [5e7].
The respiratory epithelium, besides acting as a me-
chanical barrier, also participates in the immune response
of the individual, playing an essential role in the defense of
the respiratory system [8e10]. Many cells are involved in
the immune response: epithelial cells, macrophages, neu-
trophils, B and T lymphocytes, which secrete substances
responsible for host protection [11e13].
Cytokines are extracellular signaling proteins formed by
various cells types in the body [14] that are released at the
site of inflammation, resulting in the local inflammatory
response, which is accompanied by a systemic response
known as the acute-phase response [13].
Some cytokines [13] are pro inflammatory and other,
anti-inflammatory mediators [15] and the balanced action
of these two patterns is crucial for the proper functioning
of the immune system [16e20].
Cigarette smoking is a potent pro-inflammatory stimulus
and has been implicated in the activation of a complex in-
flammatory cascade resulting in the production of a variety of
potent chemokines and cytokines [21,22] interfering in the
balance of pro-and anti-inflammatory cytokines [23].
Several studies have been shown increased levels of
cytokines such as interleukin 6 (IL-6), interleukin 8 (IL-8)
and tumor necrosis factor alpha (TNF-a) in induced sputum,
mononuclear cells and serum of healthy smokers compared
to non-smokers [14,23,24]. However, there are few studies
on the differences between local and systemic inflamma-
tion behavior in healthy smokers after smoking cessation.
Besides interfering with immune function, chronic
exposure to cigarette smoke causes respiratory tract
epithelial remodeling, with an increase of goblet cells and
hypertrophy of mucous cells, which leads to a considerableincrease in the amount of mucus to be transported and, in
addition, ciliated cells also undergo changes, with reduced
number and beat frequency of their cilia. These changes
imply in mucociliary clearance impairment [25e27].
Mucociliary clearance is an important defense mecha-
nism of the respiratory system, since entraps and expels the
inhaled aggressor agents. Some studies have reported that
chronic smokers have decreased mucociliary clearance
[28e31]. However, a previous study noted that this mech-
anism can recover in a period of 15 days without exposure
to cigarette smoke [32].
Thus, in summary, smoking has an alarming comprehen-
siveness worldwide and promotes important health hazards,
as the impairment of lung defense mechanisms. Neverthe-
less, it is known that smoking cessation can bring health
benefits, but there are few studies concerning the nasal and
systemic inflammation; as well as the mucociliary clearance
behavior in smokers after short period of smoking cessation.
The purpose of this study was to evaluate the systemic
and nasal inflammatory markers and mucociliary clearance
behavior in 30 days of cigarette smoking abstinence.Methods
Study sample
Twenty-five smokers of both genders, withmore than 20 years
of smoking history, who were enrolled in the Smoking Cessa-
tion Programme [32] of Sa˜o Paulo State University (UNESP)
from November, 2010 to January, 2011 were included in this
study. The sample size required for the study was based on a
preliminary study [21]. Our analysis indicated a sample size of
25 participants to detect changes in TNF-a after smoke
cessation with the significance level of 5% and the absolute
error of 2.5. During the treatment of smoking cessation, those
individuals who quit smoking composed the abstinent group
and those who could not quit composed the current smoker
group.All subjects receivedthe sameintervention for smoking
cessation, but in thebaselineevaluation, itwas notpossible to
known who would or not to stop smoking.
All participants were notified in advance about the ob-
jectives and procedures of the study and after their
approval, signed an informed consent in accordance with
the Declaration of Helsinki of the World Medical Association
to become part of effective research. This study was
approved by the Ethics Committee in Research (13/2010) of
the UNESP, Presidente Prudente, Brazil and by Brazilian
Clinical Trials Registry (RBR-6rzhnh). Individuals with cystic
fibrosis, bronchiectasis, asthma, COPD, immotile cilia syn-
drome, history of nasal surgery or trauma, upper airway
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certified by spirometry were excluded.
Study design and protocol
Subjects included in this studywereevaluatedat thePhysical
Therapy and Rehabilitation Clinic at UNESP by a first inter-
view conducted to obtain personal data, smoking history
(years of smoking, cigarettes/day and pack years index) and
level of dependence according to Fagerstrom questionnaire,
[33] besides to assess the lung function by spirometry [34].
The levels of exhaled carbon monoxide (exCO), carbox-
yhemoglobin (HbCO) and mucociliary clearance were
assessed and the amount of cytokines: tumor necrosis factor
alpha (TNF-a), interleukin 6 (IL-6), interleukin 8 (IL-8) and
interleukin 10 (IL-10) were determined through nasal lavage
and blood plasma samples. These evaluations were carried
out in twomoments: at baseline (when all subjects still were
maintaining their smoking habits, but under 12 h of absti-
nence) and after 30 days. The evaluations of current smokers
and abstinent smokers groups were performed at the same
moments, but the current smokers subjects did not change
their smoking habits (they just were under 12 h of absti-
nence), and the abstinent were under 30 days of abstinence.
All subjects were instructed not to use pharmacological
agents such as anesthetics, analgesics, barbiturates, tran-
quilizers, antidepressants, as well as alcohol and caffeine-
based substances during the last 12 h preceding the test.
Current smokers were also asked not smoke during the last
12 h preceding the evaluations in order to exclude the
acute effect of smoking.
Evaluations were performed in the morning (from 8 to 9
am); the temperature was set at 24 C and the relative
humidity from 50 to 60% to avoid variation in the analyzed
parameters.
Lung function
Spirometry was performed according to the guidelines of
the American Thoracic Society, using a portable spirometer
(Spirobank-MIR, Italy, version 3.6) [34]. We used specific
reference values for the Brazilian population [35].
Exhaled carbon monoxide and carboxyhemoglobin
The exCO and HbCO were measured using a CO analyser
(Micro CO Meter, Cardinal Health, UK) [36]. Subjects were
instructed to take a deep breath, remain in apnea for 20 s,
engage the mouthpiece of the device in his mouth and then
perform a slow exhalation [37].
Mucociliary clearance
For the measurement of nasal mucociliary clearance,
saccharin transit time test (STT) was used, as previously
described by Salah et al., 1988 [38]. The subjects were
seated with their head extended at 10 and granulated
sodium saccharin (250 mg) was deposited under visual con-
trol at about 2 cm inside of the right nostril. Nasal muco-
ciliary clearance was measured as the time it took for
subjects to perceive a sweet taste. If no response wasreported after 30 min, the test was concluded after con-
firming the subject had normal sweet taste perception by
placing saccharin powder directly on the tongue. In-
dividuals were instructed not to breath deeply, talk, cough,
sneeze or sniff during the test.
Determination of the amount of cytokines
Nasal lavage
For nasal lavage collection it was asked patients to incline
their head back and then make a pause in breathing for ten
seconds. Three milliliters and half of saline at room tem-
perature were instilled into each nostril using a 10 ml
disposable syringe. After 10 s the patients flexed their neck
and the liquid were expelled into a sterile plastic container
[39]. The material was transferred to graduated conical
tubes immersed in ice, and then homogenized in a Vortex
for 15 s. After this the samples were placed in a refriger-
ated centrifuge at 4 C under rotation 1000  g for
10 min and the supernatant aspirated and stored in 1.5 ml
eppendorf tubes at 70 C.
Blood plasma
Two milliliters of blood were collected from the antecubital
vein in dry tube by a skilled professional, left undisturbed
for 15 min at room temperature and centrifuge at 600 g for
total separation of serum which was collected, coded and
frozen at 70 C.
Levels of TNF-a, IL-6, IL-8 and IL-10 in blood plasma and
nasal lavage were measured by using an enzyme linked
immunosorbent assay (ELISA) kits (Duo Set, R & D System,
Minneapolis, MN) according to the manufacturer’s
instruction.
Statistical analysis
The descriptive statistics consisted of mean values, stan-
dard deviation, median and interquartile range. Compari-
sons between groups were made by Student’s t test for
independent data and Levene’s test was used to correct
distortions caused by different sample sizes. In the statis-
tical analyzes concerning the behavior of variables after 30
days, we compared the differences between the two pe-
riods of study, using the formula: Final Value - Initial Value,
which were named numeric deltas (D). Data analysis was
performed using SPSS (Version 13.0) and all procedures
considered significance values (p) of less than 5%.
Results
Twenty-five individuals were divided into two groups:
abstinent smokers (n Z 14, 49  11 years) and
current smokers (n Z 11, 41  10 years). At baseline
abstinent smokers and smokers were similar in age,
BMI (27  4  27  4 kg/m2), lung function (FEV1/FVC
(%) Z 79  9  80  13; FEV1 (%
prev) Z 92  13  96  17), smoking history (Pack/
years Z 30 [20e44]  21 [14e29]) and nicotine
dependence data (Fagerstrom score 5 [4e7]  5 [3e6]),
inflammatory markers concentration on nasal lavage
(TNF-a Z 11  4  10  5; IL-6 Z 31  11  30  10;
1002 F.M.M. Rodrigues et al.IL8Z 107  37  127  74; IL-10Z 11  5  12  7 pg/ml)
and blood serum samples (TNF-a Z 11  3  7  3; IL-
6 Z 0.18  0.15  0.36  0.17; IL-8 Z 9  5  7  7; IL-
10 Z 13  4  12  7 pg/ml), as well as STT
(16  7  10  4 min), exCO (17  7  20  8 ppm) and
HbCO values (3  2  3  1 (%)). Baseline characteristics
are summarized in Table 1. After 30 days, seven individuals
remained abstinent, five individuals relapsed before
reaching 15 days of abstinence and two individuals relapsed
after seven days of abstinence. Among the current smokers,
seven individuals completed the 30 days of follow up
(Fig. 1). After 30 days, the variables behavior (D) were
compared and abstinent smokers presented lower values ofTable 1 Anthropometric characteristics, smoking history,
spirometric values, exCO, HbCO, STT and concentrations of
inflammatory markers in abstinent and current smokers.
Abstinent
smokers
Current
smokers
Mean  SD Mean  SD
Anthropometric characteristics
Men (%) 13 27
Age (years) 49.14  11.09 41.73  9.93
BMI (kg/m2) 27.31  3.77 26.56  3.56
Spirometric values
FEV1/FVC (%) 79.16  9.25 79.73  13.17
FEV1 (L) 2.48  0.79 2.67  0.58
FEV1 (% prev) 91.69  12.76 96.36  17.16
FVC (L) 3.10  0.75 3.67  0.76a
FVC (%prev) 97.19  9.87 102.30  11.90
Smoking history
Cigarretes/dayb 20 [18.00e26.25] 15 [12.00e20.00]
Years smokedb 30 [23.50e38.50] 28 [21.45e34.25]
Pack/yearsb 30 [19.75e44.25] 21.50
[13.94e29.16]
Nicotine
dependenceb
5 [4.00e7.00] 5 [3.25e6.25]
Inflammatory markers
Blood serum
TNF-a (pg/ml) 11.01  3.24 7.31  3.41
IL-6 (pg/ml) 0.18  0.15 0.36  0.17
IL-8 (pg/ml) 9.14  5.05 6.74  6.74
IL-10 (pg/ml) 12.70  4.45 11.65  7.36
Nasal lavage
TNF-a (pg/ml) 11.13  4.00 10.21  4.95
IL-6 (pg/ml) 31.26  11.25 29.52  9.63
IL-8 (pg/ml) 107.40  37.13 126.6  73.93
IL-10 (pg/ml) 10.63  5.48 11.90  7.23
STT (min) 15.62  7.24 10.33  4.43
exCO (ppm) 17.25  7.38 19.67  8.02
HbCO (%) 2.76  1.81 3.15  1.28
SD: standard deviation; BMI: Body Mass Index; FEV1: forced
expiratory volume in first second; FVC: forced vital capacity;
exCO: exhaled carbon monoxide; HbCO: carboxyhemoglobin;
STT: saccharin transit time test; TNF-a: tumor necrosis factor
alpha; IL-6: interleukin 6; IL-8: interleukin 8; IL-10: interleukin
10.
a p < 0.05 versus abstinent smokers.
b Values expressed as Median [interquartile range].
Figure 1 Study sample flow chart.TNF-a in blood serum compared to current smokers
(6  5  3  4); as well as nasal mucociliary clearance
(8  8  1  6), exCO (15  8  0  2) and HbCO
(2  1  0  0.32) (p < 0.05 for all) (Fig. 2). There were
no differences between groups in the behavior of others
inflammatory markers in blood serum and in none of them
in nasal lavage (Table 2).
Discussion
This study showed that 30 days of abstinence was sufficient
for decrease delta concentration of TNF-a in blood serum of
abstinent smokers and improve their numeric delta of
mucociliary clearance when compared to smokers who
maintained the habit, despite no changes on the nasal
lavage TNF-a levels’.
Smoking exerts its primary effects in the respiratory
tract and leads to the activation of an inflammatory
cascade in the upper and lower airway epithelium that is
associated with the development of various diseases such
as cancer and COPD [40e42]. Even the asymptomatic
smokers exhibit signs of inflammation as manifested by
increased numbers of macrophages, neutrophils, and
CD8 þ T cells in the airway epithelium when compared with
non-smokers [43e45].
Although there are some differences among the studies
[21,23,46,47], there is a tendency of the results to show a
greater inflammatory picture in healthy smokers, with
higher levels of TNF-a, IL-8 and IL-6 in the bronchoalveolar
lavage fluid (BALF), incubated blood cells and blood serum
than in non-smokers.
At baseline, the concentrations of inflammatory markers
(TNF-a, IL-6, IL-8 and IL-10) in blood serum and nasal lavage
were similar between the groups, what was expected, since
no subjects had quit smoking at this moment. However, in
the 30 days of abstinence there was a significant decrease
in the TNF-a level in the blood serum of abstinent smokers
when compared to active smokers.
Figure 2 Delta values of tumor necrosis factor alpha level in blood serum (D sTNF-a); nasal mucociliary clearance (D STT);
exhaled carbon monoxide (D exCO) and carboxyhemoglobin (D HbCO) after 30 days of abstinence or smoking. There was a
decreased of these parameters in abstinent compared to current smokers (*p < 0.05). Data are presented as marginal mean.
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phages, monocytes and Th1 cells and plays an essential role
in the inflammatory response, being considered an impor-
tant factor in the development of lung injury secondary to
smoking [17,48,49].
Despite divergences in the literature regarding the
concentration of inflammatory markers in healthy smokers,
smoking is an important pro inflammatory stimulus, which
leads smokers to have higher levels of systemic inflamma-
tion than those who do not smoke, with higher concentra-
tions of circulating TNF-a. As this cytokine appears to play a
key role in the pathogenesis of COPD, a disease potentially
caused by smoking, and to be related to systemic mani-
festation of this disease, downregulation of this cytokine
may bring benefits to the COPD management or even pre-
vent its development [24,49].Table 2 Comparison of numerical deltas of inflammatory
markers’ concentration between abstinent and current
smokers groups.
Abstinent smokers Current smokers p
Inflammatory markers
Blood serum
TNF-a 5.55  5.23 3.40  3.90a 0.015
IL-6 0.06  0.14 0.01  0.10 0.469
IL-8 0.21  5.43 1.73  9.90 0.937
IL-10 2.32  11.09 3.84  6.87 0.844
Nasal lavage
TNF-a 0.56  5.54 4.81  9.22 0.312
IL-6 5.66  27.31 3.48  21.54 0.437
IL-8 7.082  92.07 74.99  83.84 0.812
IL-10 7.64  10.75 8.84  1.92 0.062
TNF-a: tumor necrosis factor alpha; IL-6: interleukin 6; IL-8:
interleukin 8; IL-10: interleukin 10.
a p < 0.05 versus abstinent smokers.The fact that the decrease of the TNF-a have occurred
only in blood serum without concomitance with the nasal
lavage can be related to the findings of Pelegrino et al.,
[24] where regression analyses indicated that serum levels
of TNF-a are mainly affected by active smoking, whereas
sputum concentrations are affected by COPD. Thus, as our
sample was composed by smokers without lung function
impairment, the smoking cessation only interfered with the
serum levels of these cytokine.
The study conducted by Ohkawara et al. [50] showed
that after an antigen challenge, there was a rise in TNF-a,
with peak levels detected at 3 h in serum and 6 h in BALF of
a mice model. It is of interest to note that TNF-a levels in
BALF were 6-fold greater than those in serum suggesting
considerable compartmentalization. Despite the differ-
ences between systemic and local levels of TNF-a at
baseline had not been found in our study the TNF-a changes
after 30 days of quitting smoking needed a lower time to be
detected.
Regarding the anti-inflammatory response, IL-10 has
been described the major cytokine released from Th2
[24,51] cells and is decreased in the BALF of rats exposed to
cigarette smoke. Further, IL-10 levels in sputum of healthy
smokers, asthmatic and COPD patients are lower compared
with control subjects, suggesting that inhibition of IL-10
induces inflammatory patterns in lung diseases
[15,41,52,53].
However, in this study, there was no change in nasal
and systemic release of IL-10 after a month of tobacco
smoking abstinence. Other studies also found no change in
this pattern after interventions as performing strenuous
exercise in patients with COPD and using systemic cortico-
steroids combined with inhaled b2 agonists and anticho-
linergics in the management of COPD exacerbation [54].
It is feasible that the concentration of IL-10, as of others
pro inflammatory cytokines, IL-6 and IL-8 did not change
possibly due to the short interval of smoking abstinence so
there would be change in the pattern of release of such
1004 F.M.M. Rodrigues et al.mediators. Also, the lack of a nonsmoker group prevented
us from knowing if these markers values in healthy smokers
were at normal levels.
The impairment in smokers’ mucociliary clearance has
been observed in previous studies. Cigarette smoking alters
the ciliary beat frequency and thus its efficiency. Defi-
ciency in this clearance system leads to increased fre-
quency and severity of respiratory tract infections
[28,55e59].
The mucociliary clearance improvement in 30 days of
abstinence may have occurred because of reversibility in
cilia acting or mucus physical chemical composition, since
their perfect interaction is determinant in mucociliary
functioning [60]. Cigarette smoke is highly toxic and gen-
erates the release of reactive oxygen species that modify
the physiological condition of the respiratory epithelium
and therefore mucociliary clearance [61,62]. When this
chronic exposure to aggressive agents present in cigarette
smoke is ceased, this defense mechanism can be recov-
ered. This finding corroborates the results of Ramos et al.,
2011 [29] that also presented improvement in mucociliary
clearance after smoking cessation.
It was also observed a decrease in exCO and HbCO levels
in abstinent smokers compared to those who continued
smoking. They reached the literature acceptable cut levels
[63], proving they really maintained smoking abstinence
during the evaluation period.
The measurement of exCO is an immediate, noninvasive
and well established method to distinguish smokers from
non-smokers. However, the cutoff for determination of
smoking vary in the literature, often established between 8
and 9 parts per million (ppm) in accordance with personal
characteristics [37,64e66]. It has been reported that pa-
tients with asthma and chronic obstructive pulmonary dis-
ease (COPD) have higher limits of exCO (10e11 ppm) for
classification as non-smokers compared with individuals
without lung disease (6 ppm) [63,67].
Although we evaluated the smokers who kept smoking
habits as a form of control for the analysis of inflammatory
markers in the smoking abstinence, we can point out as a
limitation of the study the lack of a non-smoker group. Such
group could add information about the condition of inflam-
matory markers in the absence of tobacco smoke exposure
and strengthen the inferences related to the no change in
the concentrations of cytokines IL-6, IL-8 and IL-10.
Conclusion
The short term smoking abstinence decreased systemic
inflammation and improved nasal mucociliary clearance,
despite not having changed the nasal inflammation.
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